Clinical Trials
24 trialsTesting the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
National Cancer Institute (NCI)
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Laguna Biotherapeutics, Inc.
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
City of Hope Medical Center
PREeMPT
Medical College of Wisconsin
Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance)
University of Utah
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
University of Pittsburgh
ENKLA-M
Nantes University Hospital
MYELO-CAN:ABX
University of Manitoba
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
University of Miami
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
CHIS
Assistance Publique - Hôpitaux de Paris
MDS
Thomas Jefferson University
GRACE
University of Manchester
IFN-α in Relapse Prevention.
Peking University People's Hospital
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS
University of Colorado, Denver
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
Peking University People's Hospital
ROVER-01
Ryvu Therapeutics SA
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Institute of Hematology & Blood Diseases Hospital, China
TMLI-MA
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
TMLI-RI
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
ACHIEVE2
TC Biopharm
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
First Affiliated Hospital of Zhejiang University
BMP-MDS
Hospices Civils de Lyon